Emerging Neuropsychiatric Toxicities of Opioids

REFERENCES

• Portenoy R K. Cancer pain-epidemiology and symptoms. Cancer 1989; 63: 2298–2307
   PubMed Web of Science ®Google Scholar
• Zenz M, Willweber-Strumpf A. Opiophobia and cancer pain in Europe. Lancet 1993; 341: 1075–76
   PubMed Web of Science ®Google Scholar
• Von Roenn J M, Cleeland C S, Gorin R, Hatfield A K, Pandya K. J. Physicians attitudes and practice in cancel pain management: a survey from the Eastern Cooperative Oncology Group. Ann Intern Med 1993; 119: 121–26
   PubMed Web of Science ®Google Scholar
• Cancer Pain Relief, Second Edition. World Health Organization. Switzerland, Geneva 1996
   Google Scholar
• Management of Cancer Pain. Clinical Practice Guidelines. AHCPR Publications, No. 94–0592, March, U.S. Department of Health, & Human Services, Rockville, MD 1994
   Google Scholar
• Cancer pain: a monograph on the management of cancer pain. Health, & Welfare Canada: Minister of Supply and Services Canada. 1984, Ottawa H42–2/5E
   Google Scholar
• Levy M H. Pharmacologic treatment of cancer pain. New Engl J Med 1996; 335: 1124–32
   PubMed Web of Science ®Google Scholar
• Bruera E, Macmillan K, Hanson J, MacDonald R N. Palliative care in a cancer center: results in 1984 vs. 1987. J Pain Symptom Manage 1990; 5(1)1–5
   PubMedGoogle Scholar
• Portenoy R K. Opioid therapy for chronic nonmalignant pain: Current status. Progress in Pain Research and Management, H L Fields, J C Liebeskind. IASP Press, Seattle 1994; 1
   Google Scholar
• American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 3rd Edition. American Pain Society, Skokie IU 1992
   Google Scholar
• Zenz M, Strumpf M, Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage 1992; 7: 69–77
   PubMed Web of Science ®Google Scholar
• Portenoy R K. Management of common opioid side effects during long term therapy of cancer pain. Annals Academy of Medicine 1994; 23(2)160–70
   PubMedGoogle Scholar
• Inturrisi C E, Hanks G WC. Opioid analgesic therapy. Textbook of Palliative Medicine, D Doyle, G Hanks, N MacDonald. Oxford University Press, Oxford 1993; 166–182
   Google Scholar
• Sjogren P, Jakobsen S, Valentin N. Respiratory depression during epidural morphine treatment. Acta Anaesthesiol Scand 1991; 35: 553–5
   PubMedGoogle Scholar
• Osborne R, Joes S, Slevin M. Morphine intoxication in renal failure: the roleofmorphine-6-glucuronide. BMJ 1986; 292: 1548–1549
   PubMed Web of Science ®Google Scholar
• Cooper A, White D, Matthay R. Drug-induced pulmonary disease. Am Rev. Resp Disease 1986; 133: 488–505
   PubMed Web of Science ®Google Scholar
• Frand V, Shim C, Williams M. Methadone-induced pulmonary edema. Ann Intern Med 1972; 76: 975–979
   PubMed Web of Science ®Google Scholar
• Bruera E, Miller M J. Non-cardiogenic pulmonary edema after narcotic treatment for cancer pain. Pain 1989; 39: 297–300
   PubMedGoogle Scholar
• Leipzig R M, Goodman H, Gray G, et al. Reversible, narcotic-associated mental status impairment in patients with metastatic cancer. Pharmacol 1987; 35: 47–54
   PubMed Web of Science ®Google Scholar
• Coda B A, Hill H F, Hunt E B, Kerr E B, Jacobson R C, Chapman C R. Cognitive and motor function impairments during continuous opioids analgesic infusions. Humar Psychopharmacol 1993; 8: 383–400
   Web of Science ®Google Scholar
• Bruera E, Macmillan K, Hanson J, et al. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989; 39: 13–16
   PubMed Web of Science ®Google Scholar
• Sjogren P, Banning A M, Christensen C B, et al. Continuous reaction time after single dose, long-term oral and epidural opioid administration. European J of Anaesthesiology 1994; 11: 95–100
   PubMedGoogle Scholar
• Vainio A, Ollila J, Matikainen E, et al. Driving ability in cancer patients receiving long-term morphine analgesia. The Lancet 1995; 346: 667–70
   PubMed Web of Science ®Google Scholar
• Zacny J P, Lichtor J L, Flemming D, Coalson D W, Thompson W K. A dose-response analysis of the subjective, psychomotor and physiological effects of intravenous morphine in healthy volunteers. J Pharmacol Exp Ther 1994; 268: 1–9
   PubMed Web of Science ®Google Scholar
• Zacny J P, Lichtor J L, Thapar P, Coalson D, Flemming D, Thompson W K. Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers. J Pharmacol Exp Ther 1994; 270(2)579–89
   PubMed Web of Science ®Google Scholar
• O'Neill W M. The cognitive and psychomotor effects of opioid drugs in cancer pain management. Cancer Surveys 1994; 21: 67–84
   PubMedGoogle Scholar
• Roache J D. Performance and physiological measures in abuse liability evaluation. Br J Addic 1991; 86: 1595–1600
   PubMedGoogle Scholar
• Fainsinger R, Miller M J, Bruera E. Morphine intoxication during acute reversible renal insufficiency. J Palliat Care 1990; 6(2)52–53
   Google Scholar
• Fainsinger R, Schoeller T, Briskin M, et al. Cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care 1993; 9: 53–55
   PubMedGoogle Scholar
• Bruera E, Miller L, McCallion J, et al. Cognitive failure (CF) in patients with terminal cancer: a prospective study. J Pain Symptom Manage 1992; 7(4)192–5
   PubMed Web of Science ®Google Scholar
• Hanks G W, O'Neill W M, Simpson P, Wesnes K. The cognitive and psychomotor effects of opioid analgesics: II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects. European Journal of Clinical Pharmacology 1995; 48: 455–460
   PubMed Web of Science ®Google Scholar
• O'Neill W M, Hanks G W, White L, Simpson P, Wesnes K. The cognitive and psychomotor effects of opioid analgesics: I. A randomized controlled trial of single doses of dextropropoxyphere, lorazepam and placebo in healthy subjects. European Journal of Clinical Pharmacology 1995; 48: 447–453
   PubMed Web of Science ®Google Scholar
• Borgbjerg F M, Nielsen K, Frans J. Experimental pain stimulates respiration and attenuates morphine-induced respiratory depression: a controlled study in human volunteers. Pain 1996; 64: 123–128
   PubMed Web of Science ®Google Scholar
• Pereira J, Hanson J, Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer 1977; 79(4)835–42
   Google Scholar
• Bruera E, Schoeller T, Montejo G. Organic hallucinosis in patients receiving high doses of opioids for cancer pain. Pain 1992; 48: 397–399
   PubMed Web of Science ®Google Scholar
• Paix A, Coleman A, Lees J, et al. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 1995; 63: 263–269
   PubMedGoogle Scholar
• Caraceni A, Martini C, De Conno F, et al. Organic brain syndromes and opioid administration for cancer pain. J Pain Symptom Manage 1994; 9: 527–33
   PubMed Web of Science ®Google Scholar
• Crawford R D, Baskoff J D. Fentanyl-associated delirium in man. Anesthesiology 1980; 53: 168–69
   PubMedGoogle Scholar
• Lowe G R. The phenomenology of hallucinations as an aid to differential diagnosis. Br J Psychiatr 1973; 123: 621–33
   PubMed Web of Science ®Google Scholar
• Breitbart W, Bruera E, Chochinov H, Lynch M. Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer. J Pain Symptom Manage 1995; 10(2)131–41
   PubMed Web of Science ®Google Scholar
• Stiefel F C, Holland J C. Delirium in cancer patients. Int Psychogeriatr 1991; 3: 333–6
   PubMedGoogle Scholar
• Lipowski Z J. Update on delirium. Psychiatr Clin North Am 1992; 15: 335–46
   PubMed Web of Science ®Google Scholar
• Breitbart W, Passik S D. Psychiatric aspects of palliative care. Oxford Textbook of Palliative Medicine, D Doyle, G Hanks, N MacDonald. Oxford University Press, Oxford 1993; 609–626
   Google Scholar
• Larson E B, Kukull W A, Buchner D, Reifler B V. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Int Med 1987; 107: 169–173
   PubMed Web of Science ®Google Scholar
• Goodwin J S, Regan M. Cognitive dysfunction associated with naproxen and buprofen in the elderly. Arthritis Rheum 1982; 25(8)1013–5
   PubMed Web of Science ®Google Scholar
• Tune L E, Carr S, Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiat 1992; 149: 1393–4
   PubMed Web of Science ®Google Scholar
• Perez E L, Silberman M. Delirium: the often overlooked diagnosis. Int J Psychiatry Med 1984; 14(3)181–9
   Google Scholar
• Smith M J, Breitbart W S, Platt M M. A critique of instruments and methods to detect, diagnose, and rate delirium. J Pain Symptom Manage 1995; 10(1)37–77
   Google Scholar
• Marsden C D, Hallet M, Fahns S. The nosology and pathophysiology of myoclonus. Movement Disorders, C D Marsden, S Fahns. Butterworth, London 1982; 196–248
   Google Scholar
• Shohami E, Evron S. Intrathecal morphine induces myoclonic seizures in the rat. Acta Pharmacol et toxicol 1985; 56: 50–54
   PubMedGoogle Scholar
• Glavina M J, Robertshaw R. Myoclonic spasms following intrathecal morphine. Anaesthesia 1988; 43: 389–90
   PubMedGoogle Scholar
• De Conno F, Caraceni A, Martini C, et al. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991; 47: 337–9
   PubMed Web of Science ®Google Scholar
• Sjogren P, Dragsted L. Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand 1993; 37: 780–2
   PubMed Web of Science ®Google Scholar
• Potter J M, Reid D B, Shaw R J, et al. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs. Br Med J 1989; 299: 150–3
   PubMedGoogle Scholar
• Sjogren P, Jonsson T, Jensen N-H, et al. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993; 55: 93–97
   PubMed Web of Science ®Google Scholar
• Parkinson S K, Bailey S L, Little W L, et al. Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiol 1990; 72: 743–5
   PubMedGoogle Scholar
• MacDonald N, Der L, Allan S, et al. Opioid hyperexcitability: the application of alternate opioid therapy. Pain 1993; 53: 353–5
   PubMed Web of Science ®Google Scholar
• Eisele J H, Grigsby E J, Dea G. Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report. Pain 1992; 49: 231–2
   PubMedGoogle Scholar
• Babul N, Darke A C. Putative role of hydromorphone metabolites in myoclonus. Pain 1993; 52: 123
   Google Scholar
• Kaiko R F, Foley K M, Grabinski P Y, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983; 13: 180–5
   PubMed Web of Science ®Google Scholar
• Hochman M S. Meperidine-associated myoclonus and seizures in long-term hemodialysis patients. Ann Neurol 1983; 14(5)27
   PubMedGoogle Scholar
• Bowdle T A. Myoclonus following sufentanil without EEG seizure activity. Anesthes 1987; 67: 593–5
   PubMed Web of Science ®Google Scholar
• Rao T, Mummaneni N. Convulsions: an unusual response to intravenous fentanyl administration. Anesth Analg 1982; 61: 1020–1
   PubMed Web of Science ®Google Scholar
• Van Praag H, Falcon M, Guendelman D, Frenk H. The development of analgesic, pro-and anti-convulsant opioid effects in the rat. Ann 1st Super Sanita 1993; 29(3)419–29
   PubMedGoogle Scholar
• Lauretti G R, Ahmad I, Pleuvry B J. The activity of opioid analgesics in seizure models utilizing N-methyl-DL-aspartic acid, kainic acid, bicuculline and pentylenetetrazol. Neuropharmacol 1994; 33: 155–60
   PubMedGoogle Scholar
• Koide S, Onishi H, Katayama M, Yamagami S. Endogenous methionine enkephalin may play an anticonvulsant role in the seizure-susceptible El mouse. Neurochem Res 1993; 18: 1259–62
   PubMedGoogle Scholar
• Koide S, Onishi H, Yamagami S, Kawakita Y. Effects of morphine and D-Ala2-D-Leu5-enkephaIin in the seizure-susceptible El mouse. Nuerochem Res 1992; 17: 779–83
   PubMedGoogle Scholar
• Sjogren P, Erikson J. Opioid toxicity. Current opinion in Anesthesiology 1994; 7: 465–469
   Google Scholar
• Inturrisi C E. Opioid analgesic therapy in cancer pain. Advances in Pain Research, & Therapy, K. M Foley, J J Bonica, V. Ventafridda. Raven Press, New York 1990; 16: 133–154
   Google Scholar
• Osterwalder J J. Naloxone-for intoxications with intravenous heroin and heroin mixtures—harmless or hazardous? A prospective clinical study. Clinical Toxicology 1996; 34(4)409–416
   Google Scholar
• Sjogren P, Jensen N-H, Jensen T-S. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994; 59: 313–3
   PubMed Web of Science ®Google Scholar
• Ali N MK. Hyperalgesic response in a patient receiving high concentrations of spinal morphine. Anesthes 1986; 65: 449
   PubMed Web of Science ®Google Scholar
• Stillman M J, Moulin D E, Foley K. E. Paradoxical pain following high-dose spinal morphine. Pain 1987; 4: S389
   Google Scholar
• Yaksh T L, Harty G J. Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. J Pharmacolog, & Experi Therapeutics 1987; 244(2)501–507
   Google Scholar
• Woolf C J. Intrathecal high dose morphine produces hyperalgesia in the rat. Brain Res 1981; 209: 491–5
   PubMed Web of Science ®Google Scholar
• Gong Q, Hedner T, Hedner J, et al. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur J Pharmacol 1991; 193: 47–56
   PubMed Web of Science ®Google Scholar
• Yaksh T L, Harty G J, Onofrio B M. High dose of spinal morphine produce a nonopioid receptor-mediated hyperesthesia: clinical and theoretic implications. Anesthesiology 1986; 64: 590–597
   PubMed Web of Science ®Google Scholar
• Glare P A, Walsh T D. Clinical pharmacokinetics of morphine. Therap Drug Monitoring 1991; 13: 1–23
   PubMed Web of Science ®Google Scholar
• Labella F S, Pinsky C, Havlicek V. Morphine derivatives with diminished opioid receptor potency have enhanced central excitatory activity. Brain Res 1979; 174: 263–271
   PubMed Web of Science ®Google Scholar
• Smith M T, Watt J A, Crammond T. Morphine-3-glucuronide a potent antagonist of morphine analgesia. Life Sci 1990; 47: 579–585
   PubMed Web of Science ®Google Scholar
• Gong Q L, Hedner J, Bjorkman R, Hedner T. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992; 48: 249–55
   PubMed Web of Science ®Google Scholar
• Hewett K, Dickenson A H, McQuay H J. Lack of effect of mor-phine-3-glucuronide on the spinal antinociceptive actions of morphine in the rat: an electrophysiological study. Pain 1993; 53: 59–63
   PubMed Web of Science ®Google Scholar
• Osborne R J, Joel S, Trew D, Slevin M. Analgesic activity of mor-phine-6-giucuronide. The Lancet 1988; 828
   PubMedGoogle Scholar
• Pasternak G W, Bodnar R J, Clark J A, Inturrisi C E. Morphine-6-glucuro-nide, a potent Mu agonist. Life Sciences 1987; 41: 2845–49
   PubMed Web of Science ®Google Scholar
• Abbott F V, Palmour R M. Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats. Life Sciences 1988; 43: 1685–95
   PubMed Web of Science ®Google Scholar
• Bartlett S E, Dodd P R, Smith M T. Pharmacology of morphine and mor-phine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites. Pharmacol, & Toxicol 1994; 75: 73–81
   PubMedGoogle Scholar
• Bartlett S E, Crammond T, Smith M T. The excitatory effects of mor-phine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABA receptor complex. Life Sci 1994; 54: 687–694
   PubMed Web of Science ®Google Scholar
• Werz M A, MacDonald R L. Opioid alkaloids antagonize postsynaptic glycine and GABA responses: correlation with convulsant action. Brain Res. 1982; 236: 107–119
   PubMed Web of Science ®Google Scholar
• Pelligrino D A, Riegler F X, Albrecht R F. Ventilatory effects of fourth cerebroventricular infusions of morphine-6- or tnorphinc-3-glucuronide in the awake dog. Anesthesiology 1989; 71: 936–40
   PubMed Web of Science ®Google Scholar
• Hanna M H, Peat S J, Woodham M, Knibb A, Fung C. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. British J of Anaesthesia 1990; 64: 547–50
   PubMed Web of Science ®Google Scholar
• Portenoy R K, Thaler H T, Inturrisi C E, Friedlander-Klar H, Foley K M. The metabolite morphine-6-glucuronidc contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther 1992; 51(4)422–31
   PubMed Web of Science ®Google Scholar
• Osborne R J, Joel S P, Slevin M L. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. British Med Journal 1986; 292: 1548–49
   PubMed Web of Science ®Google Scholar
• Hagen N A, Foley K M, Cerbhone D J, et al. Chronic nausea and inor-phine-6-glucuronide. J Pain Symptom Manage 1991; 6: 125–28
   PubMed Web of Science ®Google Scholar
• Tiseo P J, Thaler H T, Lapin J, Inturrisi C H, Portenoy R K, Foley K M. Mor-phine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61: 47–54
   PubMed Web of Science ®Google Scholar
• Glare P A, Walsh T D, Pippenger C E. Normorphine, a neurotoxic metabolite?. Lancet 1990; 335: 725–6
   PubMed Web of Science ®Google Scholar
• Babul N, Hagen N, Baker T. Hydromorphone metabolite: accumulation in renal failure. J Pain Symptom Manage 1995; 10(3)184–6
   PubMed Web of Science ®Google Scholar
• Mather L E. Clinical pharmacokinetics of Fentanyl and its newer derivatives. Clinical Pharmacokinetics 1983; 8: 422–446
   PubMed Web of Science ®Google Scholar
• Kuzma P J, Kline M D, Stamatos J M, Auth D A. Acute toxic delirium: an uncommon reaction to transdermal Fentanyl. Anesthesiology 1995; 83(4)869–871
   PubMedGoogle Scholar
• Steinberg R B, Gilman D E, Johnson F., III. Acute toxic delirium in a patient using transdermal fentanyl. Anesth Analg 1992; 75: 1014–6
   PubMedGoogle Scholar
• Bruera E, Pereira J. Clinical note: acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain. Pain, (in press)
   Google Scholar
• Mao J, Price D D, Mayer D J. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995; 62: 259–274
   PubMed Web of Science ®Google Scholar
• Mao J, Price D D, Mayer D J. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase. C J Neurosci 1994; 14: 2301–2312
   PubMed Web of Science ®Google Scholar
• Szeto H H, Inturrisi C E, Houde R, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Annals of Internal Medicine 1977; 86: 738–41
   PubMed Web of Science ®Google Scholar
• Hasselstrom J, Berg U, Lofgren A, et al. Long lasting respiratory depression induced by morphine-6-glucuronide?. Br J Clin Pharmacol 1989; 27: 515–8
   PubMed Web of Science ®Google Scholar
• Portenoy R K, Foley K M, Stulman J, et al. Plasma morphine and mor-phine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady state concentrations and the consequences of renal failure. Pain 1991; 47: 13–9
   PubMed Web of Science ®Google Scholar
• Rane A, Sawe J, Pacifier G M, et al. Regio-selective glucuronidation of morphine and interactions with benzodiazepines in human liver. Adv Pain Res Ther 1984; 8: 1297–1300
   Google Scholar
• Dahlstrom B E, Paalzow L K. Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the rat. J Pharmacokinetic Biopharm 1978; 6: 506–19
   Google Scholar
• Hanks G W, Hoskin P J, Aherne G W, et al. Entero-hepatic circulation of morphine. Lancet 1988; 469–71
   PubMedGoogle Scholar
• Ventafridda V, Ripamonti C, De Conno F, et al. Antidepressants increase bioavailabitity of morphine in cancer patients. Lancet 1987; 1204
   PubMedGoogle Scholar
• McQuay H J, Carroll D, Faura C C, et al. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 1990; 48: 236–44
   PubMed Web of Science ®Google Scholar
• Picotte-Prillmayer D, Di Maggio J, Baile W F. H2 blocker Delirium. Psychosomatics 1995; 36(1)74–7
   PubMedGoogle Scholar
• Burchell B, Coughtrie W H. UDP-glucuronosyltransferases. Pharmac Ther 1989; 43: 261–89
   PubMed Web of Science ®Google Scholar
• de Stoutz N D, Bruera E, Suarez-Almazor Maria. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995; 10: 378–84
   PubMed Web of Science ®Google Scholar
• Bruera E, Franco J, Maltoni M, Watanabe S, Suarez-Almazor M. Changing pattern of agitated impaired mental status in patients with advanced cancer: association and cognitive monitoring, hydration, and opioid rotation. J of Pain Symptom Manage 1995; 10(4)287–91
   PubMedGoogle Scholar
• Galer B, Coyle N, Pasternak W, Portenoy R. Individual variability in the response to different opioids: report of five cases. Pain 1992; 49: 87–91
   PubMed Web of Science ®Google Scholar
• Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 1996; 12(3)1828
   Google Scholar
• Eisendrath S J, Goldman B, Douglas J, et al. Meperidine-induced delirium. Am J Psychiatry 1987; 144: 1062–65
   PubMed Web of Science ®Google Scholar
• Bruera E, Velasco-Leiva A, Spachynski K, Fainsinger R, Miller M J, MacEachem T. The use of the Edmonton Injector (EI) for parenteral opioid management of cancer pain: a study of 100 consecutive patients. J Pain Symptom Manage 1993; 8(8)525–528
   PubMedGoogle Scholar
• Fainsinger R L. From the literature. How should we use transdermal fentanyl (TF) for pain management in palliative care patients?. Journal of Palliative Care 1996; 12(1)48–53
   PubMedGoogle Scholar
• Fainsinger R L. Decreased opioid doses used on a palliative care unit. Journal of Palliative Care 1996; 12(4)6–9
   PubMedGoogle Scholar
• Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain 1993; 52: 137–47
   PubMed Web of Science ®Google Scholar
• Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Cancer 1996; 78(4)852–857
   PubMed Web of Science ®Google Scholar
• Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in (he rat cortex and spinal cord. Neuroscience Letters 1995; 187: 165–168
   PubMed Web of Science ®Google Scholar
• Krug M, Matthies M, Wagner M, Brodemann. Non-opioid antitussives and methadone differentially influence hippocampal long-term potentiation in freely moving rats. Eur J Pharmacology 1993; 231: 355–361
   PubMedGoogle Scholar
• Brueva E, Macmilian K, Kuehn N, Miller M J. Circadian distribution of extra doses of narcotic analgesics in patients with cancer pain. A preliminary report. Pain 1992; 49: 311–314
   PubMedGoogle Scholar
• Bruera E, Fainsinger R, Spachynski K, Babul N, Harsanyi Z, Darke A C. Clinical efficacy and safety of a novel controlled release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Oncol 1995; 13(6)1520–27
   PubMed Web of Science ®Google Scholar
• Fainsinger R L, MacEachern T, Miller M J, et al. The use of hypodermoclysis for rehydration in terminally ill cancer patients. J Pain Symptom Manage 1994; 9: 298–302
   PubMed Web of Science ®Google Scholar
• Bruera E, Franco J J, Maltoni M, Watanabe S, Suarez-Almazor M. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration and opioid rotation. J Pain Symptom Manage 1995; 10(4)287–291
   PubMedGoogle Scholar
• Bruera E, Brenneis C, Paterson A HG, et al. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Sympt Manage 1989; 4: 3–6
   PubMedGoogle Scholar
• Forrest W, Brown B, Brown C, et al. Dextroamphetamine with morphine for the treatment of postoperative pain. New Engl J Med 1977; 296: 712–5
   PubMed Web of Science ®Google Scholar
• Bruera E, Brenneis C, Chadwick S, Hanson J, MacDonald R N. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 1987; 71(1)67–70
   PubMedGoogle Scholar
• Bruera E, Fainsinger R, MacEachem T, Hanson J. The use of methylphenidate in patients with incident cancer pain receiving regular opioids. A preliminary report. Pain 1992; 50: 75–77
   PubMed Web of Science ®Google Scholar
• Yee J D, Berde C B. Dextroamphetamine or Methylphenidate as adjuvants to opioid analgesia for adolescents with cancer. J Pain Symptom Manage 1994; 9: 122–5
   PubMedGoogle Scholar
• Krecger L, Duncan A, Cowap J. Psychostimulants used for opioid-induced drowsiness. J Pain Symptom Manage 1996; 11(1)1–2
   PubMedGoogle Scholar
• Wilwerding M B, Loprinzi C L, Mailliard J A, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer 1995; 3: 135–138
   PubMed Web of Science ®Google Scholar
• Manfredi P, Ribeiro S, Chandler S, et al. Inappropriate use of naloxone in cancer patients with pain. J Pain Symptom Manage 1996; 11: 131–4
   PubMed Web of Science ®Google Scholar
• Fainsinger R L, Tapper M, Bruera E. A perspective on the management of delirium in the terminally ill. J Palliat Care 1993; 9(3)4–8
   PubMedGoogle Scholar
• Breitbart W, Marotta R, Platt M M, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153: 231–237
   PubMed Web of Science ®Google Scholar
• De Sousa E, Jepson B A. Midazolam in terminal care. Lancet 1988; 67–8
   PubMedGoogle Scholar
• Fromm G H. Baclofen as an adjuvant analgesic. J Pain Symptom Manage 1994; 9(8)500–509
   PubMedGoogle Scholar
• Luo L, Puke M JC, Wiesenfeld-Hallin Z. The effects of intrathecal morphine and clonidine on the prevention and reversal of spinal cord hyperexcitability following sciatic nerve section in the rat. Pain 1994; 58: 245–252
   PubMedGoogle Scholar
• Krames E S, Gershow Y, Glassberg A. Continuous infusion of spinally administered narcotics for the relief of pain due to malignant disorders. Cancer 1985; 56: 696–702
   PubMedGoogle Scholar